Cargando…

Clinical efficacy of combination therapy of FuXi-Tiandi-Wuxing Decoction and anti-viral drugs in the treatment of novel coronavirus pneumonia: A prospective interventional study

INTRODUCTION: The National Administration of Traditional Chinese Medicine of the People’s Republic of China (NATCM) and the State Administration of Traditional Chinese medicine (TCM) advocated a combination therapy of TCM and anti-viral drugs for novel coronavirus pneumonia (NCP) to improve the effi...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Chen, Wenlin, Yao, Qiangyong, Kou, Li, Lanting, Jingjing, Qi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier GmbH. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9831664/
https://www.ncbi.nlm.nih.gov/pubmed/36644210
http://dx.doi.org/10.1016/j.hermed.2023.100627
_version_ 1784867893334245376
author Feng, Chen
Wenlin, Yao
Qiangyong, Kou
Li, Lanting
Jingjing, Qi
author_facet Feng, Chen
Wenlin, Yao
Qiangyong, Kou
Li, Lanting
Jingjing, Qi
author_sort Feng, Chen
collection PubMed
description INTRODUCTION: The National Administration of Traditional Chinese Medicine of the People’s Republic of China (NATCM) and the State Administration of Traditional Chinese medicine (TCM) advocated a combination therapy of TCM and anti-viral drugs for novel coronavirus pneumonia (NCP) to improve the efficacy of clinical treatment. METHODS: Forty-six patients diagnosed with NCP were sequentially divided into intent-to-treat population: the experimental group (combination of FuXi-Tiandi-Wuxing Decoction and anti-viral drugs; n = 23) and the control group (anti-viral drugs only) (n = 23). The two groups were compared in terms of duration of fever, cough symptom score, fatigue, appetite, dyspnea, out-of-bed activities, chest computer tomography (CT) recovery, virological clearance, average length of hospital stay, and clinical effective rate of drug. After 6 days of observation, patients from the control group were divided into as-treated population: experimental subgroup (n = 14) to obtain clinical benefit and control subgroup (n = 9). RESULTS: There was a significant improvement in the duration of fever (1.087 ± 0.288 vs 4.304 ± 2.490), cough (0.437 ± 0.589 vs 2.435 ± 0.662; P < 0.05), chest CT evaluation (82.6% vs 43.4%; P < 0.05), and virological clearance (60.8% vs 8.7%; P < 0.05) in patients of the experimental group compared with patients in the control group. Further observation in as-treated population reported that cough (0.742 ± 0.463 vs 1.862 ± 0.347; P < 0.05) and fatigue (78.5% vs 33.3%; P < 0.05) were significantly relieved after adding FuXi-Tiandi-Wuxing Decoction to the existing treatment. CONCLUSION: An early treatment with combination therapy of FuXi-Tiandi-Wuxing Decoction and anti-viral drugs significantly relieves the clinical symptoms of NCP, shows improvement in chest CT scan, improves virological clearance, shortens average length of hospital stay, and reduces the risk of severe illness. The effect of FuXi-Tiandi-Wuxing Decoction in NCP may be clinically important and require further consideration.
format Online
Article
Text
id pubmed-9831664
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher The Authors. Published by Elsevier GmbH.
record_format MEDLINE/PubMed
spelling pubmed-98316642023-01-11 Clinical efficacy of combination therapy of FuXi-Tiandi-Wuxing Decoction and anti-viral drugs in the treatment of novel coronavirus pneumonia: A prospective interventional study Feng, Chen Wenlin, Yao Qiangyong, Kou Li, Lanting Jingjing, Qi J Herb Med Article INTRODUCTION: The National Administration of Traditional Chinese Medicine of the People’s Republic of China (NATCM) and the State Administration of Traditional Chinese medicine (TCM) advocated a combination therapy of TCM and anti-viral drugs for novel coronavirus pneumonia (NCP) to improve the efficacy of clinical treatment. METHODS: Forty-six patients diagnosed with NCP were sequentially divided into intent-to-treat population: the experimental group (combination of FuXi-Tiandi-Wuxing Decoction and anti-viral drugs; n = 23) and the control group (anti-viral drugs only) (n = 23). The two groups were compared in terms of duration of fever, cough symptom score, fatigue, appetite, dyspnea, out-of-bed activities, chest computer tomography (CT) recovery, virological clearance, average length of hospital stay, and clinical effective rate of drug. After 6 days of observation, patients from the control group were divided into as-treated population: experimental subgroup (n = 14) to obtain clinical benefit and control subgroup (n = 9). RESULTS: There was a significant improvement in the duration of fever (1.087 ± 0.288 vs 4.304 ± 2.490), cough (0.437 ± 0.589 vs 2.435 ± 0.662; P < 0.05), chest CT evaluation (82.6% vs 43.4%; P < 0.05), and virological clearance (60.8% vs 8.7%; P < 0.05) in patients of the experimental group compared with patients in the control group. Further observation in as-treated population reported that cough (0.742 ± 0.463 vs 1.862 ± 0.347; P < 0.05) and fatigue (78.5% vs 33.3%; P < 0.05) were significantly relieved after adding FuXi-Tiandi-Wuxing Decoction to the existing treatment. CONCLUSION: An early treatment with combination therapy of FuXi-Tiandi-Wuxing Decoction and anti-viral drugs significantly relieves the clinical symptoms of NCP, shows improvement in chest CT scan, improves virological clearance, shortens average length of hospital stay, and reduces the risk of severe illness. The effect of FuXi-Tiandi-Wuxing Decoction in NCP may be clinically important and require further consideration. The Authors. Published by Elsevier GmbH. 2023-03 2023-01-11 /pmc/articles/PMC9831664/ /pubmed/36644210 http://dx.doi.org/10.1016/j.hermed.2023.100627 Text en © 2023 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Feng, Chen
Wenlin, Yao
Qiangyong, Kou
Li, Lanting
Jingjing, Qi
Clinical efficacy of combination therapy of FuXi-Tiandi-Wuxing Decoction and anti-viral drugs in the treatment of novel coronavirus pneumonia: A prospective interventional study
title Clinical efficacy of combination therapy of FuXi-Tiandi-Wuxing Decoction and anti-viral drugs in the treatment of novel coronavirus pneumonia: A prospective interventional study
title_full Clinical efficacy of combination therapy of FuXi-Tiandi-Wuxing Decoction and anti-viral drugs in the treatment of novel coronavirus pneumonia: A prospective interventional study
title_fullStr Clinical efficacy of combination therapy of FuXi-Tiandi-Wuxing Decoction and anti-viral drugs in the treatment of novel coronavirus pneumonia: A prospective interventional study
title_full_unstemmed Clinical efficacy of combination therapy of FuXi-Tiandi-Wuxing Decoction and anti-viral drugs in the treatment of novel coronavirus pneumonia: A prospective interventional study
title_short Clinical efficacy of combination therapy of FuXi-Tiandi-Wuxing Decoction and anti-viral drugs in the treatment of novel coronavirus pneumonia: A prospective interventional study
title_sort clinical efficacy of combination therapy of fuxi-tiandi-wuxing decoction and anti-viral drugs in the treatment of novel coronavirus pneumonia: a prospective interventional study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9831664/
https://www.ncbi.nlm.nih.gov/pubmed/36644210
http://dx.doi.org/10.1016/j.hermed.2023.100627
work_keys_str_mv AT fengchen clinicalefficacyofcombinationtherapyoffuxitiandiwuxingdecoctionandantiviraldrugsinthetreatmentofnovelcoronaviruspneumoniaaprospectiveinterventionalstudy
AT wenlinyao clinicalefficacyofcombinationtherapyoffuxitiandiwuxingdecoctionandantiviraldrugsinthetreatmentofnovelcoronaviruspneumoniaaprospectiveinterventionalstudy
AT qiangyongkou clinicalefficacyofcombinationtherapyoffuxitiandiwuxingdecoctionandantiviraldrugsinthetreatmentofnovelcoronaviruspneumoniaaprospectiveinterventionalstudy
AT lilanting clinicalefficacyofcombinationtherapyoffuxitiandiwuxingdecoctionandantiviraldrugsinthetreatmentofnovelcoronaviruspneumoniaaprospectiveinterventionalstudy
AT jingjingqi clinicalefficacyofcombinationtherapyoffuxitiandiwuxingdecoctionandantiviraldrugsinthetreatmentofnovelcoronaviruspneumoniaaprospectiveinterventionalstudy